Markers of Defective Membrane Remodelling in Scott-like Syndromes
Defect in Cell Stimulation and Unexplained hemorrhagesMarkers Related to Membrane Remodelling in the Prognosis Scott-like Syndormes
Sponsor: Aventis, Génopôle d'Evry.
Terminated
This trial was terminated. No reason was provided.
This observational or N/A phase trial investigates Familial Bleeding Disorder and Scott Syndrome and is currently terminated or withdrawn. Aventis, Génopôle d'Evry. leads this study, which shows 11 recorded versions since 2008 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Terminated
-
Sep 2024 — Sep 2025 [monthly]
Terminated
-
Jul 2024 — Sep 2024 [monthly]
Terminated
-
Dec 2021 — Jul 2024 [monthly]
Terminated
-
Jan 2021 — Dec 2021 [monthly]
Terminated
▶ Show 6 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Terminated
-
Jun 2018 — Nov 2020 [monthly]
Terminated
-
May 2018 — Jun 2018 [monthly]
Terminated
-
Apr 2018 — May 2018 [monthly]
Terminated
Phase: NA → None
-
Aug 2017 — Apr 2018 [monthly]
Terminated NA
-
Jan 2017 — Aug 2017 [monthly]
Terminated NA
First recorded
Jun 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Aventis, Génopôle d'Evry.
- Institut National de la Santé Et de la Recherche Médicale, France
- Louis Pasteur University, Strasbourg
- University Hospital, Strasbourg, France
For direct contact, visit the study record on ClinicalTrials.gov .